Sign in or Register
  |  

Creative Biolabs has successfully developed SARS, MERS and other anti-viral antibodies in the past to assist scientific research. Facing the difficult COVID-19, Creative Biolabs actively invests in antibody development to assist researchers to better understand the characteristics of 2019-nCoV and drug development. Currently, Creative Biolabs is proud to offer an extensive line of research antibodies to support the study of SARS-CoV-2/COVID-19, several of which were validated using virus-infected cell lysates.

Explore the collections of SARS-CoV-2/COVID-19 antibodies >

Rat Anti-KLRD1 Recombinant Antibody (15F.18D1) (CBMAB-C0390-LY)

This product is antibody recognizes KLRD1. The antibody 15F.18D1 immunoassay techniques such as: ELISA, FC, IF.
Host Species
Rat
Application
ELISA, FC, IF
Immunogen
Murine T cell clone AE7 cells
Antibody Isotype
IgG1, κ
Specificity
Mouse
Clone
15F.18D1
Format
Liquid
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.
Introduction
Natural killer (NK) cells are a distinct lineage of lymphocytes that mediate cytotoxic activity and secrete cytokines upon immune stimulation. Several genes of the C-type lectin superfamily, including members of the NKG2 family, are expressed by NK cells and may be involved in the regulation of NK cell function. KLRD1 (CD94) is an antigen preferentially expressed on NK cells and is classified as a type II membrane protein because it has an external C terminus. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2017]
Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Submit a review Submit a review and you will get a coupon.
0 reviews
Loading...

Please try the standard protocols which include: protocols, troubleshooting and guide.

Click here to view the protocols, troubleshooting and guide.

Cat CBMAB-C0390-LY
Conjugates
Size
Price $
  ADD TO CART
Request bulk or custom quote
Second antibody and isotype control